Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0000899243-19-019339
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-07-08 21:29:36
Reporting Period:
2019-07-03
Accepted Time:
2019-07-08 21:29:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1731831 Eidos Therapeutics Inc. EIDX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1262325 Eric Aguiar C/o Eidos Therapeutics, Inc.
101 Montgomery Street, Suite 2550
San Francisco CA 94104
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-07-03 882,353 $29.90 24,575,501 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
Footnotes
  1. The shares are owned by BridgeBio Pharma LLC. The Reporting Person is a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.